Continuing anti-tumor necrosis factor (anti-TNF) therapy after 24 weeks of pregnancy is associated with a lower likelihood of relapse of inflammatory bowel disease (IBD) in pregnant women and fewer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback